Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Inclusion Criteria: * Documented primary invasive breast cancer by histologic assessment * Tumors must express estrogen (ER) and/or progesterone receptors (PR) by standard immunohistochemical methods. Tumors must be negative for HER2. There must be sufficient sample for further protocol-specified immunohistochemical analysis * Patients must have high risk ER+ or PR+ breast cancer as defined by criteria listed in protocol * 18 year of age or older * Performance status of 0 or 1 by ECOG criteria * Use of an effective means of contraception in subjects of childbearing potential * Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to starting therapy. * Patients taking exogenous sex-steroid hormone treatments for any reason at the time of diagnosis must discontinue all hormonal treatments at least 2 weeks prior to enrollment * Patients must have preoperative treatment within 60 days of initial diagnosis of breast cancer * No other malignancy that requires on-going treatment * Normal organ function as outlined in the protocol Exclusion Criteria: * Prior cytotoxic chemotherapy or radiation for the current breast cancer * Patients with inflammatory breast cancer * HER2 positive disease defined as HER2-amplified by FISH or IHC 3+. HER2 2+ must be negative by FISH * Known metastatic (Stage IV) disease * Other investigational agents within 4 weeks prior to the start of study treatment * Life expectancy of less than 6 months * Peripheral neuropathy greater than or equal to grade 2 * Inadequately controlled hypertension * Any prior history of hypertensive crisis or hypertensive encephalopathy * NYHA grade II or greater congestive heart failure * History of prior myocardial infarction * History of unstable angina within 12 months prior to study enrollment * Any history of stroke or transient ischemic attack at any time * Known CNS disease * Significant vascular disease * Symptomatic peripheral vascular disease * Evidence of significant bleeding within 6 months of study; any serious non-healing wound, skin ulcers, or bone fracture; any abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months; any major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during course of study. * Known HIV positive * Unwilling to undergo pretreatment biopsy and consent to acquisition of archival tissue * Pregnant of lactating * Known hypersensitivity to any component of bevacizumab